- recruiting
Audit of Targeted Sentinel Node Biopsy (TSNB) in Patients With Limited Nodal Disease Undergoing Primary Surgery
This study looks at a new way to remove lymph nodes in breast cancer surgery, called Targeted Sentinel Node Biopsy (TSNB). It helps doctors decide if extra treatment like more surgery or radiotherapy is needed, aiming to reduce side effects.
United Kingdom - active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
United States · Australia · Belgium - not yet recruiting
An Investigation Into Dielectric Testing for the Evaluation and Characterisation of Breast Tissue Using a Novel Time-Domain Bioimpedance Tool
This study is looking at a new device called the ZedScanner. It uses gentle electrical signals to check breast tissue. Researchers want to see if it can safely and accurately tell the difference between healthy, non-cancerous, and cancerous breast tissue. It could help find new ways to detect breast cancer.
United Kingdom - active not recruitingPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
This study is for people with ovarian or breast cancer who are already receiving olaparib in a different study and are still benefiting. It allows them to continue getting their treatment if their current study ends, ensuring they keep receiving a medication that is helping them.
United States · Belgium · Bulgaria - active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
United States · Australia · Austria - active not recruitingPHASE2
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
This study looks at new ways to treat a type of breast cancer called HER2-positive. We're testing if using special drugs (Herceptin and Perjeta) without chemotherapy first can shrink tumours effectively. We're also checking if scans can predict how well treatments work.
Belgium · France · Germany - active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
This study looks at a new drug, pembrolizumab, for early-stage breast cancer. It's for people with a specific type of breast cancer (ER+/HER2-). Researchers want to see if adding pembrolizumab to standard chemotherapy and hormone therapy works better than standard treatment alone.
United States · Australia · Belgium - active not recruitingPHASE3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
This study looks at a drug called abemaciclib, given with standard hormone therapy after surgery for a type of breast cancer. We want to see if it's safe and helps stop the cancer coming back in people with certain high-risk breast cancers.
United States · Argentina · Australia - recruitingPHASE3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
This study is testing a new medicine, PF-07248144, with an existing one, fulvestrant, for advanced breast cancer that has grown despite previous treatment. It aims to see if this combination is safe and effective.
United States · Australia · Belgium - active not recruitingPHASE1
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
This study looks at a new drug, Inavolisib, for people with solid tumours or breast cancer, focusing on safety and how the body handles it. It's an early-stage study, checking if the drug works alone or with other common cancer treatments.
United States · Canada · France - active not recruitingPHASE2, PHASE3
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
This study looks at a new drug, Inavolisib, combined with standard treatments (Palbociclib and Fulvestrant) for a specific type of advanced breast cancer. It compares this new combination to the standard treatments alone, checking how well it works and if it's safe.
United States · Argentina · Australia - recruitingPHASE2
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
This study is looking at a new combination of medicines, Inavolisib and Fulvestrant, for people with a specific type of advanced breast cancer. It aims to see how well this combination works and if it's safe after other treatments haven't worked.
United States · Argentina · Australia - recruitingPHASE2
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
This study looks at new treatments for HR-positive/HER2-negative breast cancer that has been surgically removed. It uses blood tests to find tiny traces of cancer that might come back. If found, patients may get new drug combinations to see if they can stop the cancer from returning.
Spain · United Kingdom - active not recruitingPHASE1, PHASE2
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
This study looks at new drug combinations for advanced ER+ breast cancer in women aged 18-100. It tests LEE011 and BYL719 with letrozole to find safe and effective doses, hoping to improve treatment for this type of cancer.
United States · Australia · France - active not recruitingPHASE1
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
This study looks at a new combination treatment for advanced breast cancer or a type of lung cancer. It combines two drugs, Trastuzumab deruxtecan and Pembrolizumab, to see if they are safe and effective together.
United States · France · Spain - active not recruitingPHASE3
PALbociclib CoLlaborative Adjuvant Study
This study is looking at whether adding a drug called palbociclib to standard hormone therapy can improve outcomes for people with some types of early breast cancer. It's a large, international study involving many patients.
United States · Australia · Austria - active not recruitingPHASE3
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
This study looks at a new combination of medicines for postmenopausal women with a certain type of breast cancer. It tests if abemaciclib with standard hormone therapy works better than hormone therapy alone.
United States · Australia · Austria - recruitingPHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This study looks at new treatments for a type of breast cancer called triple-negative. It compares a new drug, Dato-DXd, sometimes with Durvalumab, against standard chemotherapy with Pembrolizumab for patients whose cancer has come back locally or spread.
United States · Argentina · Australia - active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This study looked at new treatments for HER2-positive breast cancer that had already been treated but still showed signs of cancer after surgery. Researchers wanted to see if adding certain drugs could prevent the cancer from coming back.
United States · Australia · Austria - active not recruitingPHASE3
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
This study compares two treatments, trastuzumab deruxtecan and trastuzumab emtansine (T-DM1), for advanced HER2-positive breast cancer. It looks at how well they work and if they are safe for patients who have already had certain other treatments.
United States · Australia · Belgium - recruitingPHASE2
KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer
This study is testing if a very diluted version of a common chemical, hydrogen peroxide, can make radiotherapy work better for large breast cancer lumps. It involves injecting this special gel into the cancer twice a week during a standard course of radiotherapy. Early results from Japan have been promising.
India · United Kingdom - recruitingPHASE2
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
This study is looking at a new combination of medicines for advanced breast cancer that has stopped responding to hormone therapy. It aims to see if combining inavolisib with ribociclib and fulvestrant works better than the current treatment.
United States · Argentina · Brazil - active not recruitingPHASE3
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
This study tests a new drug, Dato-DXd, for advanced breast cancer. It compares Dato-DXd to standard chemotherapy in women whose cancer is HR-positive and HER2-negative and has already been treated with other chemotherapy. Researchers want to see if Dato-DXd works better.
United States · Argentina · Belgium - active not recruitingPHASE1
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
This study is looking at a new drug, GDC-9545, for advanced breast cancer that has spread. It will check if the drug is safe and effective, both on its own and with other treatments. It's for women whose cancer is hormone-sensitive.
United States · Australia · South Korea - active not recruitingPHASE3
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
This study compares a new breast cancer drug, trastuzumab deruxtecan, with standard treatments. It's for people with HER2-low breast cancer that has spread or can't be removed by surgery and who have already had other treatments.
United States · Austria · Belgium - active not recruitingPHASE3
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
This study is looking at a new medicine called Dato-DXd for advanced triple-negative breast cancer. It compares Dato-DXd with standard chemotherapy in patients who cannot have a specific type of immunotherapy. The aim is to see if Dato-DXd is better at shrinking tumours and helping people live longer.
United States · Argentina · Belgium - active not recruitingPHASE2
Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
This study looks at new treatments for a specific type of breast cancer with a BRCA gene change. It tests olaparib, alone or with durvalumab, before surgery. The aim is to find better ways to treat this cancer and reduce the need for strong chemotherapy.
United States · Australia · Austria - active not recruiting
Male Breast Cancer: Understanding the Biology for Improved Patient Care
This study looks at breast cancer in men. Researchers are gathering information and samples from men with breast cancer to better understand the disease and improve how it's treated. It's a large international effort to learn more about this rare condition.
United States · Belgium · Brazil - recruitingPHASE2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is looking at a new treatment called HER3-DXd for people with certain advanced solid tumours that haven't responded to other treatments. It aims to see how well it works and if it's safe for different types of cancer, like melanoma, lung cancer, and breast cancer.
United States · Australia · Belgium - active not recruitingPHASE3
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
This study looks at new drug combinations for stage I-III triple-negative breast cancer that hasn't fully responded to initial treatment. It compares Dato-DXd with or without Durvalumab against standard treatments to see if they're more effective and safe.
United States · Belgium · Brazil - recruitingNA
HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer
This study aims to discover if a new type of scan, using a special tracer called [18F]GE-226, can effectively find and measure a specific protein called HER2 in breast cancer that has spread. We want to find the best time to do this scan and understand how safe it is.
United Kingdom - active not recruitingPHASE3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
This study is looking at a new drug, PF-07220060, combined with letrozole for advanced breast cancer. It compares this new treatment to existing approved therapies to see if it's safe and works well for people whose cancer needs hormones to grow.
United States · Argentina · Australia - recruitingPHASE3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
This study is testing a new drug, Elacestrant, against standard hormone treatments for early breast cancer. It's for men and women whose cancer is ER-positive and HER2-negative, and has a high chance of coming back. The aim is to see if Elacestrant works better.
United States · Argentina · Australia - recruitingPHASE3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
This study looks at a new drug, palazestrant, combined with standard treatment (ribociclib) for advanced breast cancer that is ER-positive and HER2-negative. It compares this new combination to the standard treatment alone to see if it works better and is safe for people who haven't had other treatments for their advanced cancer.
United States · Australia · Austria - recruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
This study is looking at new combinations of medicines for advanced lung or breast cancer. We want to see if they are safe, how much medicine gets into the body, and if they show early signs of working. It's for adults with certain types of advanced cancer.
United States · Australia · Canada - recruiting
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
This study looks at how well a special scan, called PET-CT, works on removed cancer tissue. It compares these scans with lab results and patient health over time to see if this technology can improve cancer care and treatment decisions.
Belgium · Germany · Netherlands - recruitingNA
Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
This study looks at how a blood test can help doctors decide on the best chemotherapy for early breast cancer. It aims to reduce strong treatments for patients who might not need them, improving their recovery and quality of life.
United Kingdom - active not recruitingPHASE3
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
This study looks at new drug combinations for advanced breast cancer that has grown despite previous treatments. It compares different medications, including gedatolisib, fulvestrant, and palbociclib, to see if they are safe and effective.
United States · Argentina · Australia - recruitingNA
Pilot Study of PACHA Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors
This study looks at a new programme, PACHA, to help women with breast cancer stick to their hormone treatment. It checks if the programme, run from local pharmacies, is easy to use, helpful, and could be studied on a bigger scale.
Canada - recruitingNA
Breast cancEr, FITness and ExeRcise for Heart Health: The BE-FITTER Study
This study looks at how exercise or yoga helps older women who've had breast cancer and chemotherapy. It checks if these activities can improve heart and muscle health and make daily tasks easier.
Canada - recruitingNA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
This study looks at a new, shorter radiation treatment for women whose breast cancer has come back, or who have developed a new cancer in the same breast after earlier treatment. It aims to see if this quicker, one-week course of radiation is safe and works well.
United States · Australia · Brazil - active not recruitingNA
Randomized Phase III Trial With Mepitel Film for the Prophylaxis of Radiation Dermatitis in Breast Cancer Patients
This study looks into using Mepitel Film to help prevent skin reactions during radiotherapy for breast cancer. It compares the film to standard skin care to see if it reduces problems like redness and soreness, especially for certain patients.
Canada - recruiting
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
This study looks at a new way to find small amounts of breast cancer DNA in the blood after treatment. It aims to see if this test can help predict how well high-risk breast cancer patients do over time after chemotherapy.
United States · Canada - recruitingPHASE2
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
This study is looking at new treatments for early-stage breast cancer. It focuses on a specific type of breast cancer (ER-positive, HER2-negative) that has a particular gene change (PIK3CA mutation). Researchers want to see how safe and effective the new medicine, Inavolisib, is when combined with other known treatments.
United States · Argentina · Brazil - recruitingPHASE2
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
This study is looking at a new way to treat certain breast cancers before surgery. It combines a special type of radiation with a medicine called pembrolizumab, followed by standard chemotherapy, to see if it can make treatments more effective.
Canada - not yet recruitingNA
SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors
This study looks at a special type of radiation, called SABR, for people with breast cancer that has spread. Doctors want to see if SABR can help control the cancer in the breast and surrounding areas, and if it's safe to use.
Canada - active not recruitingNA
Efficacy Study With StrataXRT for the Prophylaxis of Radiation Dermatitis in Adjuvant Breast Radiation Treatment in Large Breasted Women Using a Prone Technique
This study looks at how a special gel called StrataXRT can help prevent skin problems (like redness and soreness) for women with larger breasts having breast cancer radiotherapy. It aims to see if the gel can reduce these side effects even when women are treated lying on their front.
Canada - recruitingPHASE3
Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Prone Position
This study looks at whether a cream called betamethasone can reduce skin irritation (dermatitis) caused by radiation treatment for breast cancer. It focuses on women with larger breasts who are treated lying face down (prone position).
Canada - recruitingPHASE3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
This study looks at new drug combinations for advanced breast cancer. It compares a new treatment (gedatolisib with other drugs) to standard treatments. The aim is to find better ways to treat hormone-positive, HER2-negative breast cancer that has spread.
United States · Argentina · Australia - recruitingNA
Intelligent Vacuum Assisted Biopsy Immediately Before Surgery As an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer
This study looks at a special biopsy method for breast cancer patients who have had chemotherapy before surgery. It aims to see if this biopsy can accurately tell if cancer is gone, potentially helping doctors make better treatment plans after chemo.
Austria · Germany · Switzerland